VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company focused on innovative medicines for anxiety and depression, will participate in the Canaccord Genuity 41st Annual Growth Conference. The event includes a fireside chat with CEO Shawn Singh on August 11 at 1:30 p.m. PT. VistaGen will also engage in one-on-one meetings throughout the conference. A live webcast of the presentation will be available on the company's website. VistaGen’s drug candidates have shown promise in clinical studies and aim to advance treatment options for CNS disorders.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the Canaccord Genuity 41st Annual Growth Conference including a fireside chat with Shawn Singh, Chief Executive Officer, on Wednesday, August 11 at 1:30 p.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.
A live webcast of VistaGen’s presentation will be accessible through the News/Events page of the Investors section of the Company’s website at www.VistaGen.com.
About VistaGen
VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.
VistaGen Company Contacts
Media:
Mark McPartland
Phone: (650) 577-3606
Email: IR@vistagen.com
Investor:
Mark Flather
Phone: (650) 577-3617
Email: IR@vistagen.com
FAQ
When is VistaGen's presentation at the Canaccord Genuity 41st Annual Growth Conference?
How can I access the live webcast of VistaGen's presentation?
What is VistaGen Therapeutics focused on developing?
What is the stock symbol for VistaGen Therapeutics?
Who will represent VistaGen at the conference?
